Prognosis? Improving

Summary: Healthcare Global Enterprises has completed a decade of expansion and now enters a phase where operating leverage could significantly improve margins and returns. This story examines whether the company's discounted valuation adequately reflects the execution risks that still remain.

Summary: Healthcare Global Enterprises has completed a decade of expansion and now enters a phase where operating leverage could significantly improve margins and returns. This story examines whether the company's discounted valuation adequately reflects the execution risks that still remain. A 400 times earnings multiple is an easy no. So an investor would be right to dismiss Healthcare Global Enterprises (HCG), India’s largest cancer-focused hospital chain, at first glance. But its EV/EBITDA multiple tells a different story. At around 20 times, HCG trades at one of the lowest enterprise multiples among listed Indian hospital chains, while its peers command much richer valuations. This is not as puzzling as it looks. Hospitals are capital-intensive businesses and often carry meaningful debt, making EV/EBITDA a better valuation measure. In HCG’s case, profits have been depressed by high depreciation and finance costs, inflating the P/E. The enterprise multiple, however, suggests the company actually trades at a discount to rivals. And that discount is where we spotted a potential opportunity, as the hospital’s years of capital spending now look ready to start paying off. A moat at a discount HCG runs 25 hospitals across 19 cities, operates 38 linear accelerators (LINACs), machines used for radiation therapy, and treats close to three lakh cancer patients a year. But what makes it structurally d